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Profound modifications in the profile of patients are currently being observed within the epidemic context of AIDS,
especially with respect to pauperization and feminization of the disease. The population most frequently affected is in the
reproductive age, and among adults aged 18 to 24 years, the ratio is 1 man to 1 woman, a phenomenon occurring uniformly
all over the world. One of the main challenges for HIV-1-infected pregnant women and their doctors is the effect of the
interaction between HIV infection and pregnancy. The present article is a review of the literature; and its objective is to
assess the influence of HIV-1 infection seen from the maternal perspective, with a discussion of immunologic function,
maternal prognosis, and the HIV-abortion interface. At present, we cannot conclude that pregnancy has a short-term effect on
the evolution of HIV infection, but the concomitance of HIV and pregnancy may adversely affect the prognosis of gestation,
especially in view of its frequent association with increased abortion and puerperal morbidity rates.
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Today women represent the
populational segment with the great-
est increase in HIV infection. Most of
the infected women are in their repro-
ductive age, a fact resulting in 2,100
new infections detected daily in chil-
dren, almost all of them due to mater-
nal-fetal transmission of HIV1. How-
ever, advances have been made in the
understanding of the pathogenesis of
vertical transmission, in parallel with
significant progress against maternal-
fetal transmission of HIV, which has re-
sulted in a new opportunity to renew
and fulfill the wish to be a mother for
a large segment of the female popula-
tion. One of the major doubts to be re-
solved among doctors and patients is
the effect of HIV infection on preg-
nancy and, conversely, the effect of
this association on maternal health2.
The present article is a review of the
literature dealing with the influence of
HIV-1 infection from the maternal per-
spective, with a discussion of immu-
nologic function, the maternal and ges-
tational prognosis, and the HIV-abor-
tion interface.
INFLUENCE OF PREGNANCY ON
HIV-INFECTED WOMEN
The influence of pregnancy on im-
munologic function remains poorly
understood. During the past 10 years,
there has been concern that pregnancy
itself, either because of associated hor-
monal changes or because of a preg-
nancy-related suppression of cellular
immunity, leads to an acceleration in
the progressive decline of immune
function associated with human immu-
nodeficiency virus (HIV) infection3.
Reports of small observational series
that document clinical deterioration
during or within short periods after
pregnancy have raised concern about
a potentiating effect of pregnancy on
HIV infeccion progression4-6. From
1985 to 1988, counseling on HIV and
pregnancy was influenced by these
several negative reports which re-
flected in the recommendation of abor-
tion in countries like Sweden.7
Some studies have reported no ef-
fect of pregnancy on the rate of progres-
sion of AIDS8-15, while others have sug-
gested that an effect could exist5,6,16-18.
Currently most HIV-infected
women in the world who become preg-
nant are asymptomatic. Previous inves-
tigations of the effects of pregnancy on
HIV infection have attempted to char-
acterize the effect of pregnancy on
lymphocyte subsets, with inconsistent
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results3,19. The correlation between
lymphocyte parameters during the an-
tepartum period and the puerperium
reflects a stability of these parameters
among HIV-infected women during
pregnancy, and there is no evidence of
a major effect of pregnancy upon the
1 year postpartum outcome of HIV-in-
fected women as measured by changes
in lymphocyte subsets (total T-lym-
phocytes or in CD4+ lymphocytes)3,20-
22 
. Other investigations have sug-
gested the occurrence of an initial de-
crease and then increase or “normali-
zation” in lymphocyte subsets during
pregnancy or the postpartum pe-
riod19,23-29. Degenne et al.29 have sug-
gested that a decrease in CD4+ cells
occurs as early as the fourth week of
gestation. The response to pregnancy
of CD8+ lymphocytes is either a slight
decrease or stability throughout gesta-
tion24,26,27. Biggar et al.19 observed a
more rapid loss of CD4 cells in HIV-
infected compared to non-infected
women, with a decrease in absolute
CD4 cell count during pregnancy
through 8 weeks before delivery and
a less marked predelivery and postpar-
tum increase. Miotti et al.22 observed
no differences comparing lymphocyte
subsets in HIV-infected and uninfected
pregnant women. These authors ob-
served an increase in CD4 and CD8
cells late in pregnancy and immedi-
ately postpartum, which then de-
creased to normal by 6 weeks postpar-
tum. Tuomala et al.3 observed a dis-
crete increase in TCD4 cell count dur-
ing the antepartum period, possibly re-
flecting a tendency to an improvement
of lymphocytic parameters19,22. This el-
evation, however, does not result in an
objective normalization of immuno-
logic parameters or in the reduction of
complications related to HIV infection,
thus representing a fact of probably no
clinical relevance3.
Burns et al.30 demonstrated in a
prospective cohort of HIV-1 seroposi-
tive pregnant women (27.5% of whom
received antiretroviral therapy) that in
most women, viral load remained sta-
ble during pregnancy, but it gradually
increased post partum. A significant
rise in HIV-1 RNA levels was observed
during the second year postpartum
(mean increase 0.09 log per year; p =
0.005). Change in HIV-1 RNA was in-
dependent of the individual’s mean
HIV-1 RNA level, mean CD4 cell
level, or change in CD4 level31. There
was a steady decline in CD4 cell lev-
els during the study period. This de-
cline inversely correlated with the in-
dividual’s mean HIV-1 RNA level. The
absence of any significant overall
change in HIV-1 viral load during
pregnancy could be due to one or
more factors. A deleterious effect of the
decline of certain immune responses
during pregnancy, reported for both
HIV-1 seronegative and HIV-1 serop-
ositive women32-34 may be offset by
other immunologic changes. Preg-
nancy has been associated with altera-
tions in certain cytokines (in particu-
lar, increase in interleukin-10 which
has been reported to downregulate
HIV-1 replication), endogenous
immunomodulators that appear to be
very important in modifying HIV-1
replication35-38.
Parturition is associated with in-
creased levels of specific cytokines,
including interleukin-6 which is capa-
ble of upregulating HIV-1 replication,
but this alteration appears to be more
transient39-40.
Investigations suggest that the
level of viral load in the peripheral
blood is established after
seroconversion and remains stable un-
til it begins to rise late in HIV-1 infec-
tion41,42. This plateau level or “set
point”, which varies widely, appears to
represent the equilibrium reached be-
tween the infecting strain of the virus
and the capacity of the individual’s
immune system to contain it42,43. The
apparent stability of HIV-1 RNA lev-
els during gestation suggests that preg-
nancy has little immediate effect on
viral load in most women44.
Alliegro et al.45 evaluated the inci-
dence and outcome of pregnancy in
HIV-infected women with estimated
dates of seroconversion and compared
the risk of disease progression between
women who were pregnant during in-
fection and those who were not. From
October 1981 through December
1994, these authors did not observe
any effect of the pregnancy up to 1
year after delivery or abortion on ac-
celerated development of AIDS, HIV-
related diseases, or severe immunosup-
pression during pregnancy. Again, no
significant differences were observed
between women who were pregnant
only once when compared with those
with multiple pregnancies.
From survival analysis, it is esti-
mated that 5 years after delivery 14%
of mothers will have died, 24% will
have developed CDC Stage IV disease,
and more than 60% will still be with-
out serious HIV-related manifestations.
Women with lower CD4 counts during
pregnancy subsequently progressed to
CDC Stage IV at a faster rate than
women with higher CD4 counts.
Thorne et al.46 estimated that 66% of
the women with a CD4 count of less
than 200 cells/mm3 will progress to
stage 4 within a period of 2 years after
delivery, in contrast to only 21% of
women with a CD4 count of more than
499 cells/mm3.
In a prospective study of the effect
of pregnancy on the progression of hu-
man immunodeficiency virus infec-
tion, there was no difference in pro-
gression of disease between child-bear-
ing and non-pregnant HIV-infected
women at a 5-year follow-up10.
The CCR5 chemokine receptor
acts as a coreceptor with CD4 to per-
mit infection by primary macrophage-
tropic HIV-1 strains. The CCR5-
Delta32 mutation, which is associated
with resistance to infection in ho-
mozygous individuals and delayed
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disease progression in heterozygous
individuals, is rare in places where the
HIV-1 epidemic is growing rapidly.
Several polymorphisms in the pro-
moter region of CCR5 have been iden-
tified. In this context, John et al.47
evaluated the effect of CCR5 pro-
moter mutations on systemic and mu-
cosal HIV-1 replication, disease pro-
gression, and perinatal transmission in
a cohort of 276 HIV-1-seropositive
women in Nairobi, Kenya. These au-
thors demonstrated that women with
the 59356 C/T genotype had a 3.1-
fold increased risk of death during the
2-year follow-up period and a signifi-
cant increase in vaginal shedding of
HIV-1-infected cells, compared with
women with the 59356 C/C genotype.
INFLUENCE OF HIV-1 ON
PREGNANCY
Whether HIV-1 infection itself may
adversely affect pregnancy remains
controversial. From 1985 to 1989,
Minkoff et al.48 studied the gestational
and neonatal prognosis of 92 seroposi-
tive and 126 seronegative women who
gave birth during the study period and
did not observe any demonstrable ef-
fect of HIV infection on the gestational
prognosis. These data agree with those
reported by Selwyn et al.8, who stud-
ied American female drug users. Simi-
lar results were also reported by
Johnstone et al.11 in a study on female
drug users in Edinburgh.
A higher incidence of postpartum
genital infection in HIV-seropositive
women than in seronegative women
has been reported.49-51 The power of
the study by Minkoff et al.48 to detect
adverse effects of HIV infection on in-
frequent complications of pregnancy,
such as endometritis or toxemia, is
limited48. Sexually transmissible dis-
eases and medical complications were
diagnosed almost twice as often
among seropositive women52. After
controlling for factors such as sexually
transmissible diseases, Leroy et al.49
observed a significant increase in ad-
verse obstetrical events, such as mater-
nal postpartum haemorrhage and post-
operative endometritis, as also con-
firmed by other authors50.
Some studies have shown an asso-
ciation between HIV-1 infection and
miscarriage8,11,51,53-63, while other au-
thors do not confirm this assertive64-69.
In a systematic review of the litera-
ture and meta-analysis, Brocklehurst &
French63 observed an association be-
tween the risk of spontaneous abortion
and women infected with HIV-1 that
varied from 1.8 to 6 times greater.
Considerable evidence shows that
raised anticardiolipin antibody levels
are associated not only with throm-
boembolism but also with preterm de-
livery, intrauterin growth restriction
(IUGR), and fetal loss at all stages of
pregnancy70. Studies have also demon-
strated that raised anticardiolipin an-
tibody levels are uncommon in the
general obstetric populations (2%) and
that there is a significantly increased
risk of pregnancy wastage when they
do occur71,72.
Johnstone et al.70 in a study of
largely asymptomatic, pregnant HIV-se-
ropositive women showed that approxi-
mately 25% had abnormally raised lev-
els of anticardiolipin antibodies, com-
pared with none of the HIV-negative IV
drug users or controls. As others have
found73-75, there seemed to be no asso-
ciation between anticardiolipin anti-
bodies and length of time since
seroconversion or overt illness, and the
abnormality appeared to be a direct re-
sponse to HIV70.
Viscarello et al.76 observed that
53% of HIV-1 pregnant women were
positive for anticardiolipin antibody.
In addition, these authors did not ob-
serve association among this positivity
and adverse maternal or neonatal out-
come, maternal human immunodefi-
ciency virus status, or perinatal trans-
mission of virus-seropositive human
immunodeficiency.
It is possible that this higher
positivity for anticardiolipin antibody
is not real. It has been observed that
HIV-infected patients often exhibit
hypergammaglobulinemia, a potential
cause of false-positive results through
nonspecific binding of IgG74. Another
source of false-positive anticardiolipin
levels is heat treatment of serum77.
Adverse pregnancy outcome has
frequently been reported in HIV infec-
tion63. However, the hypothesis that part
of this effect may result from
anticardiolipin antibodies has not been
proven. The hypothesis regarding pla-
cental size is interesting, since
antiphospholipid antibodies may cause
placental thrombosis and infarction by
blocking the release of arachidonic
acid from endothelial cells and hence
inhibiting production of prostacyclin70.
It seems that there are 2 separate
populations of phospholipid antibodies
evoked by infectious and autoimmune
diseases. Anticardiolipin antibodies
evoked by infectious diseases have a
narrow specificity for anionic
phospholipids complexed to a plasma
protein cofactor, and only this group is
linked to a thrombotic tendency78-80.
Falcón et al.81 have suggested that
anticardiolipin antibodies may not
bind the cardiolipin antigen directly,
but may instead bind a plasma protein
(b2-glycoprotein I) that has high affin-
ity for anionic phospholipids. These
authors hypothesized that women with
antiphospholipid antibodies and a his-
tory of pregnancy loss would have a
higher prevalence of antibodies
against phospholipid-binding proteins
than women with antiphospholipid
antibodies and normal pregnancies.
These authors observed a significant
association between IgM anti-b2-
glycoprotein I and a history of miscar-
riages. Recurrent spontaneous abortion
has been observed owing to allo-
imunization82.
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There may be a direct effect of HIV-
1 on the placenta and on embriogenesis.
HIV-1 has been identified in fetuses
during the first weeks of pregnancy83,84.
The presence of HIV-1 infected mono-
cyte/macrophages in the endometrial
mucosa has also been demonstrated85.
There may be abnormalities in the fe-
tal thymus, with consequent abnormal
cytokine production secondarily result-
ing in an adverse intrauterine milieu for
the adequate maintenance of preg-
nancy, possibly due to the deleterious
effects of this event on the en-
dometrium. As a consequence, there
may also be a cumulative effect of the
immunosuppression caused by HIV in-
fection, facilitating the ascension of in-
fections from the lower genital tract and
the development of viral or bacterial
infection of the villi68. Shearer et al.86
propose that HIV infection in pregnant
women produces an altered state of cer-
tain soluble immune factors such as
cytokines, which in concert with other
immune factor abnormalities such a loss
of immune selection in the fetal thymus
predisposes the fetus to advanced HIV
infection (possibly due to an imbal-
ance of immune factors capable of con-
tributing to immunological rejection)
and possible spontaneous abortion.
CONCLUSION
Current data suggest that preg-
nancy bears no effect on accelerating
the development of AIDS, HIV-related
diseases, or severe immunosuppression
during pregnancy for up to 1 year af-
ter delivery or abortion. On the other
hand, HIV infection may adversely af-
fect pregnancy, especially in terms of
the overall risk of spontaneous abor-
tion and maternal postpartum en-
dometritis. It would be a useful prac-
tice to conduct long-term follow-up on
all HIV-infected pregnancies.
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Atualmente, dentro do contexto epi-
dêmico da AIDS observam-se profundas
modificações no perfil dos pacientes
acometidos, especialmente traduzida
pela pauperização e feminilização. A
população mais afetada encontra-se em
idade reprodutiva e entre adultos de 18
a 24 anos, a relação é de 1 homem para
1 mulher, o que ocorre indiscrimi-
nadamente como fenômeno global. Um
dos maiores desafios para as gestantes
portadoras do HIV-1 e seus médicos as-
sistentes é a repercussão advinda da
interação entre a infecção pelo HIV e a
gestação. Esse artigo é uma revisão de
literatura e tem por objetivos avaliar a
influência da infecção pelo HIV-1 sob
a perspectiva materna tecendo conside-
rações sobre a função imunológica, o
prognóstico materno e a interface HIV
e abortamento. Até o presente, não se
pode concluir que a gestação tenha, a
curto prazo, um efeito norteador da
evolução da infecção pelo HIV, porém
a concomitância HIV e gestação pode
adversamente afetar o prognóstico
gestacional, especialmente face à fre-
qüente associação com acréscimo nos
índices de aborto e morbidade
puerperal.
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